预测贝伐珠单抗抗肿瘤治疗效果的生物学标记物

Bevacizumab, the monoclonal antibody of vascular endothelial growth factor (VEGF) has been applied to the therapy of several neoplasms, but an appropriate biomarker to predict the efficacy has not been found. Tose markers can originate from peripheral circulation, tumor tissue and genes. Some researches have found that low level of vascular cell adhesion molecule-1 (VCAM-1), E-selectin, angiopoietin 2 (Ang-2) in circulation or carbonic anhydrase 9 (CA9), CD31- microvessel density (CD31-MVD) in tumor tissue can predict beter activity of bevacizumab. Moreover, high level of soluble VEGFR2 (sVEGFR2) in circulation or the ratio of phosphorylated-VEGFR2 (p-VEGFR2) and VEGFR2 in tumor tissue increasing has the same predictive function. As to the gene, VEGF-634 CC, VEGF-1498 T and VEGFR2 H472Q are only related to the side effct. Thus more clinical tirals and basic researches should be performed to fnd out effective biomarkers in bevacizumab's therapy.